Market Closed -
Nasdaq
21:00:00 26/04/2024 BST
|
5-day change
|
1st Jan Change
|
1.89
USD
|
+0.53%
|
|
+5.59%
|
-11.27%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,889
|
646.7
|
320.7
|
285.6
|
-
|
-
|
Enterprise Value (EV)
1 |
1,475
|
211.1
|
320.7
|
102.8
|
48.3
|
-31.37
|
P/E ratio
|
-8.42
x
|
-2.17
x
|
-2.57
x
|
-2.12
x
|
-1.93
x
|
-1.81
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
299
x
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
50.6
x
|
-
|
EV / EBITDA
|
-11.9
x
|
-0.86
x
|
-
|
-0.62
x
|
-0.24
x
|
0.15
x
|
EV / FCF
|
-15
x
|
-1.76
x
|
-
|
-0.83
x
|
-0.3
x
|
0.17
x
|
FCF Yield
|
-6.68%
|
-56.8%
|
-
|
-120%
|
-329%
|
579%
|
Price to Book
|
2.26
x
|
1.28
x
|
-
|
1.02
x
|
1.18
x
|
1.49
x
|
Nbr of stocks (in thousands)
|
121,250
|
150,054
|
150,572
|
151,122
|
-
|
-
|
Reference price
2 |
15.58
|
4.310
|
2.130
|
1.890
|
1.890
|
1.890
|
Announcement Date
|
24/03/22
|
23/03/23
|
27/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
0.9541
|
-
|
EBITDA
1 |
-
|
-124.1
|
-244.8
|
-
|
-165.4
|
-199.3
|
-212.5
|
EBIT
1 |
-
|
-124.9
|
-247.4
|
-141.5
|
-156
|
-180.7
|
-200.2
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-18,940.88%
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-122.8
|
-242.8
|
-125
|
-136.1
|
-158.3
|
-185.6
|
Net income
1 |
-101.7
|
-122.8
|
-242.8
|
-125
|
-142.6
|
-168.5
|
-185.6
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-17,659.74%
|
-
|
EPS
2 |
-4.836
|
-1.850
|
-1.990
|
-0.8300
|
-0.8933
|
-0.9785
|
-1.042
|
Free Cash Flow
1 |
-
|
-98.48
|
-119.8
|
-
|
-123.8
|
-159
|
-181.6
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-16,663.87%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
25/06/21
|
24/03/22
|
23/03/23
|
27/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-45.85
|
-30.73
|
-36.1
|
-35.37
|
-36.19
|
-137.1
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-46.04
|
-31.05
|
-36.5
|
-35.9
|
-36.96
|
-138.1
|
-37.02
|
-35.97
|
-34.66
|
-33.87
|
-35.31
|
-36.57
|
-38.02
|
-39.2
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-46.07
|
-30.46
|
-36.46
|
-35.61
|
-35.49
|
-135.2
|
-33.2
|
-31.78
|
-30.36
|
-29.7
|
-30.5
|
-32.17
|
-33.73
|
-35.53
|
-
|
Net income
1 |
-46.07
|
-30.46
|
-36.46
|
-35.61
|
-35.49
|
-135.2
|
-33.2
|
-31.78
|
-30.36
|
-29.7
|
-30.92
|
-32.25
|
-34.2
|
-35.92
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.4600
|
-0.2600
|
-0.3100
|
-0.3000
|
-0.2900
|
-1.060
|
-0.2200
|
-0.2100
|
-0.2000
|
-0.2000
|
-0.1983
|
-0.2103
|
-0.2263
|
-0.2191
|
-0.2500
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/11/21
|
24/03/22
|
12/05/22
|
11/08/22
|
09/11/22
|
23/03/23
|
15/05/23
|
10/08/23
|
09/11/23
|
27/03/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
414
|
436
|
-
|
183
|
237
|
317
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-98.5
|
-120
|
-
|
-124
|
-159
|
-182
|
ROE (net income / shareholders' equity)
|
-
|
-71.7%
|
-55.9%
|
-
|
-42.8%
|
-54.6%
|
-67.5%
|
ROA (Net income/ Total Assets)
|
-
|
-39.2%
|
-47.8%
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
313.1
|
508.2
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
6.890
|
3.380
|
-
|
1.860
|
1.600
|
1.270
|
Cash Flow per Share
2 |
-
|
-1.200
|
-0.8500
|
-
|
-0.9000
|
-1.160
|
-
|
Capex
1 |
-
|
18.9
|
16.6
|
-
|
2.43
|
2.78
|
3.41
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
290.87%
|
-
|
Announcement Date
|
25/06/21
|
24/03/22
|
23/03/23
|
27/03/24
|
-
|
-
|
-
|
Last Close Price
1.89
USD Average target price
7
USD Spread / Average Target +270.37% Consensus |
1st Jan change
|
Capi.
|
---|
| -11.27% | 286M | | +1.51% | 42.75B | | +8.57% | 41.34B | | +49.22% | 41.61B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|